Dicarbamyl Iodoacetamides as Antitumor Compounds ID: 2014-080
A novel class of compounds offering a promising avenue for cancer therapy.
Photo by starlineart - stock.adobe.com
Technology Overview
This technology involves the development of dicarbamyl iodoacetamides, a new class of chemical compounds with significant antitumor properties. Developed at Brigham Young University, these compounds are characterized by their unique chemical structure, which has been shown to be effective against various cancer cell lines, including lung adenocarcinoma. The invention encompasses the compounds' synthesis, chemical structure, and potential applications in antitumor compositions.
Key Advantages
- Novel chemical structure with potent antitumor activity
- Proven efficacy against various cancer cell lines in vitro, including lung adenocarcinoma
- Potential for development into a new class of cancer therapeutics
Problems Addressed
- Lack of specificity and efficacy in existing antitumor compounds
- Need for new chemical entities in the fight against cancer
- Challenges in targeting specific cancer cell lines with current treatments
Market Applications
- Pharmaceutical development of antitumor drugs
- Research and development in cancer treatment therapies
- Use in laboratory settings for cancer cell line testing and drug discovery
Additional Information
Technology ID: 2014-080
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 07 May, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report